Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Suspended 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 657Carcinoma, Renal Cell 385Carcinoma, Non-Small-Cell Lung 243Urinary Bladder Neoplasms 235Breast Neoplasms 221Melanoma 193Ovarian Neoplasms 192Neoplasms 178Colorectal Neoplasms 161Kidney Neoplasms 152Neoplasm Metastasis 131Carcinoma, Transitional Cell 127Pancreatic Neoplasms 124Lung Neoplasms 121Stomach Neoplasms 114Squamous Cell Carcinoma of Head and Neck 107Sarcoma 99Head and Neck Neoplasms 89Uterine Cervical Neoplasms 88Carcinoma, Hepatocellular 80Triple Negative Breast Neoplasms 76Esophageal Neoplasms 76Endometrial Neoplasms 75Colonic Neoplasms 64Wilms Tumor 56Small Cell Lung Carcinoma 55Carcinoma, Ovarian Epithelial 48Neuroblastoma 47Liver Neoplasms 46Testicular Neoplasms 45

Interventions

talazoparib 1olaparib 1CX 5461 1BAY 2315497 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration Resistant Prostate Cancer (mCRPC) × Genitourinary × Clear all
NCT07621692 2026-06-02

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

National Taiwan University Hospital

Phase 1 Recruiting
12 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03874884 2025-05-14

LuPARP

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting
70 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03724747 2024-11-08

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Bayer

Phase 1 Completed
63 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05425862 2023-12-11

REPAIR

Peter MacCallum Cancer Centre, Australia

Phase 1 Suspended
48 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡